US · LPCN
Lipocine Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- Salt Lake City, UT 84108
- Website
- lipocine.com
Price · as of 2024-12-31
$2.33
Market cap 55.3M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $302.70 | +12,891.42% |
| Intrinsic Value(DCF) | $3.35 | +43.78% |
| Graham-Dodd Method(GD) | $3.94 | +69.14% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | $135.15 | $30,601.21 | |||
| 2014 | $112.54 | ||||
| 2015 | $175.95 | ||||
| 2016 | $68.00 | ||||
| 2017 | $26.86 | ||||
| 2018 | $35.02 | $0.00 | $0.00 | ||
| 2019 | $9.64 | $14.82 | $0.00 | $0.00 | $432.30 |
| 2020 | $28.22 | $21.62 | |||
| 2021 | $26.01 | $12.51 | $12.84 | ||
| 2022 | $5.24 | $145.96 | $4.16 | $0.00 | $182.39 |
| 2023 | $3.61 | $103.79 | $0.00 | $0.00 | $1,964.02 |
| 2024 | $3.44 | $302.70 | $3.29 | $3.94 |
AI valuation
Our deep-learning model estimates Lipocine Inc.'s (LPCN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $302.70
- Current price
- $2.33
- AI upside
- +12,891.42%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.35
+43.78% upside
Graham-Dodd
$3.94
+69.14% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LPCN | Lipocine Inc. | $2.33 | 55.3M | +12,891% | +44% | +69% | — | 2199.00 | 0.87 | 1.64 | 2.93 | — | 0.87 | 100.00% | -10.31% | 0.07% | 0.04% | 92.79% | 0.04% | 0.00 | — | 14.75 | 14.38 | 5.57 | -9995.00% | -49280.00% | -8896.00% | -7.14% | -0.81 | 113.94% | 0.00% | 0.00% | 7.81% | 2.83 | 2.49 | -0.29 | -3.70 |
| ANL | Adlai Nortye Ltd. | $7.86 | 245.52M | +169% | — | — | — | -0.47 | 0.97 | — | 0.19 | — | 0.97 | 0.00% | — | — | -98.90% | -2580.88% | -51.49% | 1.07 | -28.22 | 1.41 | 1.37 | 0.70 | -6829.00% | -10000.00% | -855.00% | -211.30% | -1.14 | -2444.23% | 0.00% | 0.00% | 0.00% | 0.17 | 0.17 | — | -10.34 |
| BLRX | BioLineRx Ltd. | $2.83 | 12.31M | +2,367% | — | — | — | -27.55 | 18.87 | 8.78 | 63.67 | — | 84.33 | 67.99% | -70.52% | -31.86% | -69.11% | 441.68% | -17.93% | 1.12 | -2.23 | 1.76 | 1.52 | 1.18 | -8723.00% | 50292.00% | 9178.00% | -17.29% | -2.85 | 950.70% | 0.00% | 0.00% | 1.08% | -12.22 | -5.68 | 8.62 | -9.02 |
| EDSA | Edesa Biotech, Inc. | $2.20 | 18.37M | — | — | — | — | -1.39 | 0.80 | — | 0.11 | — | 0.95 | 0.00% | — | — | -99.57% | -603.13% | -82.86% | 0.00 | — | 10.67 | 10.60 | 1.53 | -3420.00% | — | 4973.00% | -73.29% | -6.79 | -558.20% | 0.00% | 0.00% | 97.84% | 0.10 | 0.11 | — | -2.27 |
| ERNA | Ernexa Therapeutics Inc. | $0.29 | 2.24M | +35,680% | +510% | — | — | -2.77 | 72.62 | 212.25 | -3.39 | — | -360.15 | 83.51% | -2693.13% | -7652.75% | -2264.31% | -84.37% | -163.74% | 0.40 | -2.32 | 0.80 | 0.74 | 0.03 | -6152.00% | 75588.00% | -2067.00% | -13.12% | -5.39 | -87.22% | 0.00% | 0.00% | 28.59% | -7.81 | -7.56 | 210.46 | -50.59 |
| GOVX | GeoVax Labs, Inc. | $1.60 | 1.62M | — | +969% | — | — | -0.35 | 1.76 | 2.24 | -0.14 | — | 1.78 | 97.59% | -635.83% | -631.98% | -462.31% | 4381.85% | -286.62% | 0.00 | -1176.34 | 2.55 | 1.98 | 0.22 | -5284.00% | — | -209.00% | -278.43% | -7.94 | 4303.75% | 0.00% | 0.00% | 0.00% | -0.13 | -0.14 | 0.85 | -29.47 |
| LNAI | Lunai Bioworks Inc. | $0.37 | 6.59M | — | — | — | — | -0.19 | -1.60 | — | -2.38 | -1.04 | -1.24 | 0.00% | — | — | -321.81% | -29.94% | -207.76% | -0.48 | -25.56 | 0.04 | 0.02 | -0.55 | 1846.00% | — | -2868.00% | -23.05% | -0.27 | -12.71% | 0.00% | 0.00% | 0.00% | -2.36 | -5.57 | — | -97.67 |
| MBRX | Moleculin Biotech, Inc. | $2.39 | 2.89M | — | — | — | — | -0.18 | 0.64 | — | 0.00 | — | -0.75 | 0.00% | — | — | -135.80% | -1009.89% | -78.93% | 0.08 | — | 0.97 | 0.80 | 0.14 | -5806.00% | — | -144.00% | -619.14% | -4.45 | -905.04% | 0.00% | 0.00% | 0.00% | 0.00 | 0.00 | — | -17.68 |
| OSRH | OSR Holdings, Inc. | $0.41 | 10.58M | — | — | — | — | -5.08 | -1.58 | — | -3.39 | — | -1.58 | 0.00% | — | — | -15.54% | -21.87% | -10.39% | -0.27 | 81.95 | 0.07 | 0.01 | -0.48 | -85209.00% | — | 16722.00% | -21.32% | -0.33 | -15.79% | 0.00% | 0.00% | 0.00% | -3.39 | -5.47 | — | -12.68 |
| PMN | ProMIS Neurosciences, Inc… | $23.51 | 30.74M | — | — | — | — | 7.09 | 1.19 | — | 2.23 | — | 1.19 | 0.00% | — | — | 27.46% | 589.07% | 17.08% | 0.00 | -219.18 | 8.52 | 6.04 | -4.65 | -10775.00% | — | 15067.00% | -137.99% | -12.25 | 951.55% | 0.00% | 0.00% | 3.52% | -0.38 | -0.23 | — | -3.71 |
About Lipocine Inc.
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
- CEO
- Mahesh V. Patel
- Employees
- 16
- Beta
- 1.01
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.35 ÷ $2.33) − 1 = +43.78% (DCF, example).